IMGN

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Spacecraft, Employment, Cancer, ImmunoGen, IMGN, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of January 31, 2024, the grant of restricted stock units (“RSUs”) covering 68,940 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to eleven new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, Spacecraft, ImmunoGen, Employment, IMGN, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of December 29, 2023, the grant of restricted stock units (“RSUs”) covering 167,159 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to six new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter for the next three years, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of ICVX, EAR, CVLY, IMGN to Take Action

Retrieved on: 
Wednesday, December 27, 2023
Empire, CVR, IMGN, AstraZeneca, Sale, Monteverde, EAR, ImmunoGen, AbbVie, Eargo, Security (finance)

Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.

Key Points: 
  • Under the terms of the agreement, ICVX shareholders are expected to receive $15.00 in cash and one non-tradeable CVR worth up to $5.00 per share they own.
  • Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.
  • Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
  • Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.

ALERT: The M&A Class Action Firm Continues Investigating the Merger – EAR, IMGN, CVLY, EVFM

Retrieved on: 
Thursday, December 14, 2023
Empire, IMGN, Sale, Monteverde, EAR, ImmunoGen, AbbVie, OTC, Eargo, Security (finance)

Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.

Key Points: 
  • Under the terms of the agreement, EAR shareholders will receive $2.55 in cash per share they own.
  • Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.
  • Under the terms of the agreement, CVLY shareholders are expected to own approximately 44% of the outstanding shares of the combined company.
  • Evofem Biosciences, Inc. (OTC: EVFM ), relating to its proposed sale to Aditxt, Inc. Click here for more information: https://www.monteverdelaw.com/case/evofem-biosciences-inc .

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SRC, IMGN, PATI, ROVR

Retrieved on: 
Tuesday, December 5, 2023
Patriot Transportation, Empire, Blackstone Inc., SRC, IMGN, Sale, Monteverde, ImmunoGen, Rover Group, RIC, AbbVie, Security (finance)

Under the terms of the agreement, SRC shareholders will receive 0.762 shares of RIC per share they own.

Key Points: 
  • Under the terms of the agreement, SRC shareholders will receive 0.762 shares of RIC per share they own.
  • It is free and there is no cost or obligation to you.
  • Under the terms of the agreement, IMGN shareholders will receive $31.26 in cash per share they own.
  • Under the terms of the agreement, ROVR shareholders will receive $11.00 in cash pers share they own.

SHAREHOLDER NEWS: Johnson Fistel Investigates Proposed Sale of ImmunoGen

Retrieved on: 
Thursday, November 30, 2023
LLP, Sale, ImmunoGen, Learning, AbbVie, SAN, IMGN

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ImmunoGen, Inc. (NASDAQ: IMGN) breached their fiduciary duties in connection with the proposed sale of the Company to AbbVie.

Key Points: 
  • SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of ImmunoGen, Inc. (NASDAQ: IMGN) breached their fiduciary duties in connection with the proposed sale of the Company to AbbVie.
  • You can click or copy and paste the following link to join this investigation:
    On November 30, 2023, ImmunoGen announced that it had entered a deal to merge with AbbVie.
  • Under the terms of the deal, ImmunoGen shareholders will receive $31.26 per share in cash.
  • If you are a shareholder of ImmunoGen and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker ( [email protected] ) at 619-814-4471.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Retrieved on: 
Sunday, December 10, 2023
Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Molecular Pharmacology, Fever, Associate, Azacitidine, Hypotension, Safety, CCR, Spacecraft, Pneumonia, ASH, University, Cytopenia, Disease, Cellular, Constipation, Fatigue, Mortality, Penile ultrasonography, Patient, IMGN, DNA, MRD, Medical Affairs Bureau, Pharmacokinetics, Peripheral edema, Flow cytometry, Capillary leak syndrome, MD, Diarrhea, Cancer, Nausea, Survival, Drug resistance, Transplant, AML, Apoptosis, MD Anderson Cancer Center, Society, ImmunoGen, Hypokalemia, Hypophosphatemia, Venetoclax, Rare-earth element, Pharmaceutical industry, Birth control, Vaccine, Medicinal plants, Research

These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.

Key Points: 
  • These findings will be presented in a poster session at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California.
  • “The MRD negativity rates, which are indicative of a deep remission, are particularly promising in the treated patient population.
  • Response rates and MRD negativity were numerically comparable between cohorts 1 and 2, despite differences in the venetoclax schedule.
  • We look forward to continuing to expand our cohort of newly diagnosed unfit patients to inform the development path for pivekimab in AML.”
    ImmunoGen is also presenting two preclinical posters at ASH.

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, December 5, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, National Medical Products Administration, Priority review, Annual general meeting, Food, European Medicines Agency, Spacecraft, Progression-free survival, US Foods, ADC, Patient, IMGN, ASCO, New Drug Application, Medical Affairs Bureau, ImmunoGen, MD, Cancer, Mirvetuximab soravtansine, Society, PDUFA, Pharmaceutical industry, Research

The application has been granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of April 5, 2024.

Key Points: 
  • The application has been granted Priority Review designation with a Prescription Drug User Fee Act (PDUFA) action date of April 5, 2024.
  • We look forward to collaborating closely with the FDA throughout the review process."
  • The confirmatory Phase 3 MIRASOL trial of ELAHERE in platinum-resistant ovarian cancer forms the basis of the sBLA.
  • ELAHERE was granted accelerated approval by the FDA in November 2022 based on data from the pivotal SORAYA trial.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 1, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Cancer, Employment, IMGN, ImmunoGen, Spacecraft, RSU, Vaccine

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of November 30, 2023, the grant of restricted stock units (“RSUs”) covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to twelve new employees.

Key Points: 
  • ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”) approved, effective as of November 30, 2023, the grant of restricted stock units (“RSUs”) covering 112,252 shares of ImmunoGen’s common stock under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the “Inducement Plan”) to twelve new employees.
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • Each RSU will vest as to 25% of the shares underlying the RSU award on the first anniversary of the grant date and as to an additional 25% of the shares underlying the RSU award annually thereafter, subject to the employee’s continued employment on each vesting date.
  • Each RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of an RSU agreement covering the grants.

IMGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ImmunoGen, Inc. Is Fair to Shareholders

Retrieved on: 
Thursday, November 30, 2023
Class Action Lawsuit, Professional Services, Legal, AbbVie, Sale, Fraud, ImmunoGen, IMGN, Advertising

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ImmunoGen, Inc. (NASDAQ: IMGN) to AbbVie Inc. for $31.26 per share in cash is fair to ImmunoGen shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ImmunoGen, Inc. (NASDAQ: IMGN) to AbbVie Inc. for $31.26 per share in cash is fair to ImmunoGen shareholders.
  • On behalf of ImmunoGen shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.